Preview: Arcus Biosciences's Earnings
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) is scheduled to release its quarterly earnings report on February 21, 2024, with an expected EPS of $-1.02. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting variably. Shares are currently trading at $16.8, marking a 16.24% decline over the last year. Investors are looking for positive guidance for the next quarter.
February 20, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Arcus Biosciences is expected to report an EPS of $-1.02 for the upcoming quarter. Historical performance shows variability in stock price reaction post-earnings, with a general downtrend over the past year.
Given the expected EPS and historical performance, the short-term impact on RCUS's stock price could be neutral. While an earnings beat could provide a positive short-term boost, the overall trend and investor sentiment seem to lean towards caution, especially considering the stock's 16.24% decline over the past year. The company's guidance for the next quarter will likely play a crucial role in determining the stock's direction.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100